Clinical Trial Update: Orelabrutinib Combined With Zuberitamab in the Initial Treatment of MZL [Phase 2]

View source ↗

Summary

A Phase 2 trial is exploring orelabrutinib combined with zuberitamab as initial therapy for marginal zone lymphoma and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Marginal Zone Lymphoma

Drugs mentioned

• Orelabrutinib (orelabrutinib)
• Zuberitamab (Zuberitamab)

Snippet

Sponsor: Li Zhiming | Conditions: Initial MZL, Untreated MZL | Phase 2 | Status: RECRUITING